Variable | N = 249 (%) |
---|---|
Median age at HCT, years (range) | 56 (21–77) |
Male gender | 150 (60) |
Race | |
 Caucasian | 214 (86) |
 African American | 5 (2) |
 Othersa | 17 (7) |
 Missing | 13 (5) |
Karnofsky performance score ≥ 90 | 119 (48) |
 < 90 | 113 (45) |
 Missing | 17 (7) |
HCT-CI | |
 0 | 46 (18) |
 1–2 | 53 (21) |
 ≥ 3 | 84 (34) |
 Not available before 2007 | 55 (22) |
 Missing | 11 (4) |
Interval from diagnosis to HCT, months | |
 Median (range) | 14 (3–118) |
Median lines of therapy before HCT (range) | 3 (1–5) |
Remission status at HCT | |
 Complete remission | 108 (43) |
 Partial remission | 90 (36) |
 Chemorefractory | 38 (15) |
 Untreated/unknown | 13 (5) |
History of prior autologous HCT | 98 (39) |
TBI in conditioning | 83 (34) |
ATG/alemtuzumab in conditioningb | 59 (24) |
Conditioning intensityc | |
 Myeloablative conditioning | 66 (27) |
 Non-myeloablative/RIC | 183 (73) |
Graft source | |
 Bone marrow | 8 (3) |
 Peripheral blood | 241 (97) |
Donor type | |
 HLA-identical sibling | 140 (56) |
 Unrelated donor 8/8 | 109 (44) |
Donor/recipient CMV status | |
 Both negative | 72 (29) |
 Both positive | 59 (24) |
 Either donor/recipient + | 69 (28) |
 Missing | 49 (19) |
Graft-versus-host disease prophylaxis | |
 Calcineurin inhibitor + MTX ± othersd (except MMF) | 119 (48) |
 Calcineurin inhibitor + MMF ± othersd | 76 (31) |
 Calcineurin inhibitor + others (except MMF) | 40 (16) |
 Othersd | 10 (4) |
 Missing | 4 (2) |
Year of HCT | |
 2000–2006 | 47 (19) |
 2007–2011 | 82 (33) |
 2012–2016 | 120 (48) |
Median follow-up of survivors (range), months | 49 (4–170) |